We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current KROS market cap is 689.03M. The company's latest EPS is USD -3.7769 and P/E is -4.52.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 8k | 143k | 83k | 37k | 388k |
| Operating Income | -43.28M | -46.46M | -48.48M | -50.44M | -58.66M |
| Net Income | -39.44M | -40.24M | -43.11M | -45.26M | -52.96M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 10M | 0 | 20.1M | 0 | 151k |
| Operating Income | -10.56M | -46.66M | -56.37M | -114.79M | -169.94M |
| Net Income | -12.34M | -45.36M | -58.74M | -104.68M | -152.99M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 326.25M | 370.03M | 485.82M | 455.02M | 579.27M |
| Total Liabilities | 30.41M | 37.81M | 31.87M | 34.11M | 46.44M |
| Total Equity | 295.84M | 332.21M | 453.95M | 420.92M | 532.84M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.96M | 269.44M | 255.25M | 306.78M | 370.03M |
| Total Liabilities | 10.46M | 7.72M | 12.08M | 29.36M | 37.81M |
| Total Equity | -19.45M | 261.72M | 243.17M | 277.42M | 332.21M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -99.05M | -124.51M | -44.56M | -84.36M | -114.86M |
| Investing | -1.92M | -2.46M | -946k | -1.26M | -1.64M |
| Financing | 109.7M | 178.96M | 156.8M | 160.33M | 316.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -16M | -36.89M | -62.15M | -70.06M | -124.51M |
| Investing | -271k | -294k | -1.02M | -1.24M | -2.46M |
| Financing | 14k | 296.04M | 28.55M | 120.31M | 178.96M |
| Market Cap | 689.03M |
| Price to Earnings Ratio | -4.52 |
| Price to Sales Ratio | 4.62k |
| Price to Cash Ratio | 2.09 |
| Price to Book Ratio | 2.08 |
| Dividend Yield | - |
| Shares Outstanding | 40.51M |
| Average Volume (1 week) | 2.64M |
| Average Volume (1 Month) | 1.75M |
| 52 Week Change | -50.47% |
| 52 Week High | 73.00 |
| 52 Week Low | 15.67 |
| Spread (Intraday) | 0.55 (3.18%) |
| Company Name | Keros Therapeutics Inc |
| Address |
850 new burton road dover, delaware 19904 |
| Website | https://www.kerostx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
